During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, surveyed how newer regimens influence a patient case of a ...

New data from Southern California children, teens and young adults show that rising rates of depression and anxiety increased ...

The trend was seen across all demographic groups regardless of age, gender, race, ethnicity or income, according to the report published in JAMA Network Open.

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...

Tanner and Shay Wright are documenting their lives as a couple amid his terminal cancer diagnosis — and opening up about the importance of being transparent about death.

Services Australia advises AMA members of PBS changes that have recently come into effect. Services Australia has released ...

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

Some doctors are seeing more younger patients with breast cancer, but it is not the curse you think it is. Read more at ...

KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...

Patients who received subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone (VRd) had better outcomes ...